Sysmex XN-Series CBC Result Interpreter & Troubleshooter

PHASE 1 — INSTRUMENT TECHNOLOGY PRIMER

(Apply silently; reference only when explaining an unexpected result)

Detection Channels on XN-Series

Key Physics Principles

• FSC (Forward Scatter) = cell volume/size
• SSC (Side Scatter) = cell internal complexity (nucleus, granules)
• SFL (Side Fluorescence) = nucleic acid content (RNA/DNA) — labelled by proprietary fluorescent dye
• Lysis reagent perforates membranes while preserving cell structure → dye penetrates → fluorescence proportional to RNA/DNA content
• WNR uses more acidic, lower-osmolarity reagent than WDF → erythrocytes lyse completely; basophils resist lysis
• RBC/PLT channel uses impedance only — cell size = voltage pulse magnitude

Why Scattergram Morphology Matters

• Normal cluster positions and tight groupings = reliable differential
• Dispersed, shifted, or fused clusters = suspect interference, sample degradation, or pathological cells
• WDF scattergram axes: SSC (y) vs SFL (x) — NEUT (upper right), LYMPH (lower left), MONO (middle), EO (upper left area), BASO/IG (variable positions)
• WNR scattergram axes: SFL (y) vs FSC (x) — WBC cluster upper right; NRBC cluster lower left; BASO cluster upper left
• RET scattergram: FSC (y) vs SFL (x) — reticulocytes show elevated SFL relative to mature RBC

PHASE 2 — REFERENCE RANGES BY AGE & SEX

Apply the correct reference range before flagging as abnormal or normal.

Adult Reference Ranges (18–65 years)

Paediatric Adjustments (flag these for attention)

Special Populations (apply as modifier)

• Pregnancy: Lower HGB threshold acceptable (≥10 g/dL in 2nd/3rd trimester); physiological leukocytosis up to 12×10³/µL; thrombocytopenia threshold raised concern at <100
• African/West African populations: Benign ethnic neutropenia — NEUT# as low as 1.0 may be physiological; evaluate in clinical context before labeling neutropenic
• Post-chemotherapy: Absolute NEUT count critical; threshold for neutropenic fever ≤0.5×10³/µL (severe <0.1)

PHASE 3 — SYSTEMATIC PARAMETER INTERPRETATION

For each result image, parse and evaluate ALL parameters in this order:

3A. RBC Line (Erythrocyte Assessment)

Step 1: Classify anemia or polycythemia

• Low HGB/RBC → Anemia. Then classify by MCV:
  • MCV <80 fL → Microcytic (Iron deficiency, thalassemia, sideroblastic, lead toxicity)
  • MCV 80–100 fL → Normocytic (Acute blood loss, hemolysis, chronic disease, aplastic anemia, early mixed deficiency)
  • MCV >100 fL → Macrocytic (B12/folate deficiency, liver disease, hypothyroidism, alcohol, drugs — hydroxyurea, methotrexate)
• High HGB/HCT/RBC → Polycythemia
  • Relative (dehydration) vs. Absolute (primary PV vs. secondary causes — hypoxia, EPO)

Step 2: RDW interpretation

• Elevated RDW-CV (>14.5%) with low MCV → Iron deficiency favored over thalassemia trait (thalassemia trait has normal/low RDW)
• Elevated RDW with normal MCV → mixed deficiency (iron + B12/folate), or early iron deficiency, or hemolysis
• Elevated RDW with high MCV → B12/folate deficiency, liver disease

Step 3: MCH/MCHC interpretation

• Low MCH + low MCHC → Hypochromia → Iron deficiency, thalassemia
• High MCHC (>36 g/dL) → Suspect: hemolysis, spherocytosis, cold agglutinins; ALSO a QC alert (see Phase 5)
• MCHC >37 → Strong indicator for blood film + repeat; possible instrument interference (cold agglutinin, lipemia, hemolysis)

Step 4: RBC histogram shape (from printout)

• Single symmetric peak: normal
• Right shift (tall peak shifted right): macrocytosis
• Left shift: microcytosis
• Broad peak: anisocytosis (elevated RDW)
• Bimodal (two peaks): dimorphic picture — mixed iron deficiency + B12/folate, or post-transfusion, or treatment response

Key MCH/MCHC Interference Table:

3B. WBC Line (Leukocyte Assessment)

Step 1: Total WBC

• <4.0 × 10³/µL → Leukopenia (investigate differential, drug history, viral infection, BM pathology)
• 4–10 → Normal
• 10–30 → Leukocytosis (infection, inflammation, steroid use, physiological stress, CML spectrum)

• 30 → Significant leukocytosis — consider CML, leukemoid reaction, leukemia

• 100 → Hyperleukocytosis — URGENT; consider blast crisis, CML, leukemia; WBC clumping/clogging artifacts possible

Step 2: Differential assessment

Step 3: NRBC assessment

• Any NRBC# >0 in adults = ABNORMAL (physiological only in neonates)
• Causes: severe hemolytic anemia, thalassemia major, sickle cell crisis, myelophthisic anemia, blast crisis, severe hypoxia
• NRBCs artificially inflate WBC on some older analyzers — XN-Series corrects WBC for NRBCs automatically; check WBC-N vs WBC-D

Step 4: IG% (immature granulocytes)

• IG% 2–5%: Monitor, correlate with clinical picture
• IG% >5%: Significant left shift — blood film mandatory
• IG% >10%: Consider CML or sepsis; urgent clinical review

3C. PLT Line (Platelet Assessment)

Step 1: PLT count

• <150 → Thrombocytopenia
  • 100–150: Mild; monitor
  • 50–100: Moderate; bleeding risk with trauma
  • 20–50: Significant risk; spontaneous bleeding possible
  • <20: Critical; spontaneous CNS/GI bleeding risk → URGENT CLINICAL ACTION

• 400 → Thrombocytosis

  • Reactive (infection, iron deficiency, post-splenectomy, inflammation) vs. primary (ET, CML)

Step 2: PLT morphology indices

• High MPV (>12.5 fL) + low PLT: Increased platelet production (ITP, hypersplenism, myeloproliferative) OR large platelet artifacts
• Low MPV (<7.5 fL) + low PLT: Aplastic anemia, chemotherapy suppression
• High PDW: Platelet anisocytosis → myeloproliferative disease, ITP
• High P-LCR: Large platelet fraction elevated → ITP, essential thrombocythemia
• High PCT (proportional to PLT × MPV): Elevated in thrombocytosis; very low in aplasia

Step 3: PLT histogram

• Right-shifted or broad peak: Large platelets (may include microerythrocytes, cell fragments)
• Peak cut off at right: Suspect microerythrocytes or RBC fragments counted as PLT → blood film required
• PLT-F vs PLT-I discordance (if available): PLT-F is more accurate at very low counts (<50×10³/µL) and when microparticles are present

PLT Interference Table:

3D. Reticulocyte Assessment (RET Channel)

RET-He Clinical Decision Tool:

• RET-He <25 pg → Definitive functional iron deficiency → Iron supplementation
• RET-He 25–28 pg → Borderline → Ferritin + TSAT
• RET-He >28 pg + low RET% → Hypoproliferative; not iron-deficient

PHASE 4 — FLAG INTERPRETATION ENGINE

4A. WBC Flags (WDF/WNR Channel)

4B. RBC Flags

4C. PLT Flags

4D. Scattergram Interpretation Rules

WDF Scattergram (SSC vs SFL):

• Tight NEUT cluster = normal; dispersed/shifted upper right = toxic granulation, reactive change
• Lymph cluster elevated SFL = reactive lymphocytes (viral)
• Blurred NEUT-MONO boundary = immature monocytes, monocytosis
• Extra cluster between NEUT and LYMPH = IG/blast population → BLOOD FILM
• Low SFL entire scattergram = abnormal Hb, reagent issue

WNR Scattergram (SFL vs FSC):

• WBC main cluster = upper right (normal)
• NRBC cloud = lower left area (small, dim fluorescence)
• Extra cloud between NRBC and WBC = immature erythroid precursors, blasts
• BASO cluster = upper left (large, high FSC)

RET Scattergram (FSC vs SFL):

• Dense cloud lower left = mature RBC
• Upper right scatter = reticulocytes (high RNA → high SFL)
• Very dense upper cloud = high reticulocyte activity (hemolysis/treatment response)
• Sparse scatter = hypoproliferative; check RET-He

PHASE 5 — INSTRUMENT QC & MAINTENANCE ASSESSMENT

5A. QC Assessment Triggers

Suspect instrument issue (not patient pathology) when:

5B. Daily QC Checklist (Remind user if QC not mentioned)

□ Run XN CHECK Level 1, 2, 3 before patient samples
□ Review Levey-Jennings charts — apply Westgard rules (1-2s warning; 1-3s reject; 2-2s reject; R-4s reject; 4-1s reject; 10x trend reject)
□ Check background count (WBC <0.2; RBC <0.02; PLT <10 acceptable)
□ Verify reagent levels (CELLPACK, STROMATOLYSER, FLUOROCELL, SULFOLYSER)
□ Check reagent expiry dates
□ Confirm temperature of analyser room (18–28°C optimal)
□ Verify sample: K₂EDTA tube, no clot, well-mixed, analyzed within 4–6 hours (RDW/MCV drift after 6h; MCHC after 8h)

5C. Calibration Trigger Criteria

Recalibrate when:

• QC mean shifts >2 SD from established mean on any parameter
• Bias exceeds CLSI EP9 allowable error for: WBC (>15%), RBC (>2.5%), HGB (>2%), HCT (>3%), PLT (>9%)
• After reagent lot change
• After major maintenance (aperture replacement, flow cell cleaning)
• When QC values show trend >5 consecutive points in same direction (Westgard)
• After power failure or instrument relocation

Calibration Parameters Requiring XN CAL: WBC, RBC, HGB, HCT, PLT, RET, RET-He
PLT-F requires XN CAL PF separately

5D. Reagent Interference Table

PHASE 6 — BLOOD FILM DECISION ENGINE

Apply the ICSH 2014 / BSH criteria for blood film review decisions.

MANDATORY Blood Film (DO NOT DELAY):

• Blasts? flag present
• Abnormal lympho/blasts? flag present
• iRBC? flag (malaria/parasite suspected — STAT thick film)
• WBC >30 or <2 × 10³/µL
• HGB <7 g/dL (severe anemia requiring morphology)
• PLT <50 × 10³/µL (critically low — confirm and morphology)
• NRBC >5% or NRBC# >1 × 10³/µL
• IG% >10%
• MCHC >37 g/dL (exclude cold agglutinin, spherocytes, artifact)
• Fragments? flag (TTP/DIC/MAHA screen)
• WBC Abn Scattergram with clinical concern

RECOMMENDED Blood Film (within same session):

• WBC 10–30 × 10³/µL with clinical concern (unexplained leukocytosis)
• Atypical Lympho? flag
• IG% 2–10%
• RDW-CV >18% (marked anisocytosis)
• PLT 50–100 × 10³/µL
• PLT >600 × 10³/µL (thrombocytosis — reactive vs. primary?)
• New significant anemia (HGB drop >2 g/dL from previous)
• Abnormal PLT histogram (peak cut off right edge)
• Monocyte count >1.5 × 10³/µL (CMML exclusion)
• Macrocytosis MCV >110 fL
• Known hemoglobinopathy with acute change

BLOOD FILM NOT REQUIRED (routine, confirm clinically):

• All parameters within reference range for age/sex
• No morphological flags
• QC in range
• Clinical context is routine screening

Blood Film Report Expectations

When sending for film, specify these morphological targets in the film request note:

RBC morphology: Hypochromia, microcytes, macrocytes, target cells, sickle cells, spherocytes, elliptocytes, schistocytes, tear-drop cells, Howell-Jolly bodies, basophilic stippling, polychromasia, rouleaux

WBC morphology: Left shift (bands, metamyelocytes), toxic granulation, Döhle bodies, hypersegmented neutrophils, blasts, abnormal/reactive lymphocytes, monocyte morphology

PLT morphology: Giant platelets, platelet clumps, satellite platelets, megakaryocyte fragments

PHASE 7 — CLINICAL CONCLUSION & ACTION PLAN FORMAT

After completing Phases 2–6, output the following structured report:

🔬 CBC ASSESSMENT REPORT — [Date/Sample ID]

Patient: Age ___ | Sex ___ | Clinical Context: ___
Instrument: Sysmex XN-3100 | Module: ___
Sample Collected: ___ | Analyzed: ___

SECTION 1: PARAMETER SUMMARY TABLE

Status icons: ✅ Normal | ⬆️ High | ⬇️ Low | ⚠️ Borderline | 🚨 Critical

SECTION 2: FLAG ANALYSIS

SECTION 3: SCATTERGRAM INTERPRETATION

WDF: [Describe cluster positions, any aberrant clusters, quality of separation]
WNR: [NRBC presence, WBC cluster quality, BASO position]
RET: [Reticulocyte cloud density, SFL distribution, evidence of active erythropoiesis]
RBC Histogram: [Peak shape, position, bimodal features]
PLT Histogram: [Peak shape, cutoff concerns]

SECTION 4: CLINICAL INTERPRETATION

Primary Finding: [e.g., Microcytic hypochromic anemia with thrombocytosis]
Differential Diagnosis (top 3):

1. [Most likely] — supported by [parameters]
2. [Second possibility] — supported by [parameters]
3. [Third possibility] — needs exclusion by [test]

Correlating Parameters: [How parameters together support the interpretation]

SECTION 5: INSTRUMENT QC ASSESSMENT

Instrument Conclusion: [e.g., "Results appear analytically reliable — no instrument flags present and QC described as passing. Proceed with clinical interpretation." OR "MCHC >37 g/dL — exclude cold agglutinin/lipemia before validating result."]

SECTION 6: BLOOD FILM DECISION

Decision: [MANDATORY NOW / RECOMMENDED / NOT REQUIRED]
Rationale: [Which flags/parameters drove this decision]
Morphological Targets: [List what to look for on the film]
Urgency: [STAT (<2 hours) / Routine (same session) / Next session]

SECTION 7: ACTION PLAN

IMMEDIATE (within 1 hour):

• [Action item e.g., "Prepare STAT blood film — iRBC? flag present, exclude malaria"]

SHORT-TERM (within same working day):

• [Action item e.g., "Repeat PLT in citrate tube — clumping suspected"]
• [Action item e.g., "Request serum ferritin, TSAT — microcytic anemia with normal RDW"]

FURTHER INVESTIGATIONS:

• [Lab tests to request e.g., B12/folate, HPLC, reticulocyte count if not done, Coombs test]
• [Imaging or clinical if needed e.g., "Refer for hepatosplenomegaly assessment — monocytosis + splenomegaly pattern"]

CLINICIAN NOTIFICATION:

• [e.g., "CRITICAL VALUE: PLT 18 × 10³/µL — Notify clinician immediately per laboratory critical value policy"]

INSTRUMENT ACTIONS:

• [e.g., "Run QC all 3 levels before next patient batch — QC status unconfirmed"]
• [e.g., "Check reagent expiry — FLUOROCELL RET due for replacement"]

SECTION 8: BRIEF CONCLUSION

[2–3 sentence plain-language summary suitable for laboratory report comment or verbal communication to clinician. Example: "This CBC shows moderate microcytic hypochromic anemia with thrombocytosis and a normal WBC differential, most consistent with iron deficiency anemia in a 35-year-old female. No instrument flags detected. A blood film is recommended to assess hypochromia and microcytosis degree, and serum ferritin with iron studies should be requested to confirm diagnosis. Results are analytically reliable — QC status should be confirmed."]

PHASE 8 — WORKED EXAMPLE (APPLIED TO SAMPLE IMAGE)

This section demonstrates how to apply the skill to a real result — use as template.

Patient context from uploaded image:

• Sample: QC-60471103 | Date: 2026/03/30 | Instrument: Sysmex XN-3100-1-R
• No age/sex provided in image → Must request from user before full interpretation

Parameter Extract from image:

• WBC: 17.10 ×10³/µL | RBC: 5.09 ×10⁶/µL | HGB: 15.3 g/dL | HCT: 44.3%
• MCV: 87.0 fL | MCH: 30.1 pg | MCHC: 34.5 g/dL | PLT: 519 ×10³/µL
• NEUT: 8.15/47.7% | LYMPH: 4.33/25.3% | MONO: 1.70/9.9% | EO: 2.10/12.3%
• BASO: 0.82/4.8% | IG: 2.04/11.9% | NRBC: 1.03 ×10³/µL (6.0%)
• RET: 1.16% | IRF: 24.6% | RET-He: 26.1 pg
• LFR: 75.4% | MFR: 21.0% | HFR: 3.6%

Preliminary interpretation (age/sex unknown — for demonstration):

WBC elevation (17.10): Leukocytosis. Differential shows relative neutrophilia, eosinophilia (12.3% = 2.10 ×10³/µL — elevated), basophilia (4.8% = 0.82 ×10³/µL — elevated), and IG 11.9% (2.04 ×10³/µL — significantly elevated). Combined picture of eosinophilia + basophilia + elevated IG strongly suggests a myeloproliferative disorder, particularly CML — requires urgent blood film and BCR-ABL1 molecular testing.

NRBC: 1.03 ×10³/µL (6.0%): Significant NRBC — blood film mandatory. In context of possible CML, NRBCs may represent leukoerythroblastic reaction.

RBC/HGB/HCT: Within reference range (assuming adult). MCHC 34.5 — normal.

PLT: 519 ×10³/µL: Thrombocytosis. Reactive or primary (essential thrombocythemia vs. CML thrombocytosis).

RET-He: 26.1 pg: Below 28 pg → Indicates functional iron deficiency — possible concurrent iron-deficient erythropoiesis despite normal HGB. Consider ferritin.

IRF: 24.6%: Elevated — indicates active erythropoiesis with young reticulocytes being released, consistent with increased marrow output.

Blood Film Decision: MANDATORY — STAT
Targets: Blasts, myeloid left shift, tear-drop cells, NRBC morphology, eosinophil morphology, basophil count, platelet morphology, any hypersegmented or dysplastic forms

Immediate Action:

1. 🚨 STAT blood film — blast/myeloproliferative screen
2. Notify clinician — pattern consistent with possible CML or myeloproliferative neoplasm
3. Request: BCR-ABL1 FISH/PCR, bone marrow referral if not known diagnosis
4. Request serum ferritin (RET-He 26.1 pg)
5. Confirm QC was run today; if uncertain, run before reporting

SKILL USAGE NOTES

Trigger phrases that activate this skill:

• "Interpret this CBC result"
• "Is a blood film needed for this result?"
• "Check my Sysmex flags"
• "Assess my hematology result"
• "Troubleshoot my analyzer output"
• "What does this CBC mean for a [age] year old [male/female]?"
• Any uploaded image of a Sysmex XN printout (identifiable by scattergram layout, parameter format, or "XN series sysmex" header)

Mandatory inputs:

1. Image of CBC result (uploaded photograph or scan)
2. Patient age (years)
3. Patient biological sex

Optional but valuable:

• Clinical context/diagnosis
• Previous CBC for comparison
• QC status of the day
• Time from collection to analysis

Output mode:

Default = Full report (Phases 2–8)
If user asks "quick summary" = Section 8 only (Brief Conclusion) + Action Plan
If user asks "just flags" = Section 2 (Flag Analysis) + Section 6 (Blood Film Decision) only
If user asks "is my instrument working?" = Section 5 (QC Assessment) only

EEHLSS / MedLabAI-LIS | Skill maintained by Echukwuka | Aligned to ICSH 2014, CLSI H20-A2, BSH 2009, ISO 15189:2022
For use in clinical laboratory practice — results must be validated by a qualified Medical Laboratory Scientist